Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases



General Best Practice Guidelines for Immunization, Part 2 Vaccine Safety

Pink Book Web-on-Demand Series July 19, 2022

A.Patricia Wodi, MD

Medical Officer

NCIRD, CDC

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Learning Objectives

- Describe the Advisory Committee on Immunization Practices General Best Practice Guidelines on Immunization.
- Describe an emerging immunization issue.
- For each vaccine-preventable disease, identify those for whom routine immunization is recommended.
- For each vaccine-preventable disease, describe characteristics of the vaccine used to prevent the disease.
- Locate current immunization resources to increase knowledge of team's role in program implementation for improved team performance.
- Implement disease detection and prevention health care services (e.g., smoking cessation, weight reduction, diabetes screening, blood pressure screening, immunization services) to prevent health problems and maintain health.

Continuing Education Information

- CE credit, go to: <u>https://tceols.cdc.gov/</u>
- Search course number: WD4564-071922
- CE credit expires: July 1, 2024
- CE instructions are available on the Pink Book Web-on-Demand Series web page
- Questions and additional help with the online CE system, e-mail <u>CE@cdc.gov</u>



Disclosure Statements

In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts, wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from any ineligible company for this continuing education activity.

Disclosure Statements

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

General Best Practice Guidelines for Immunization

ACIP Table of Contents

- Introduction
- Methods
- Timing and spacing
- Contraindications and precautions
- Preventing and managing adverse reactions to immunization
- Vaccine administration
- Storage and handling
- Altered immunocompetence
- Special situations
- Vaccination records
- Vaccination programs
- Vaccine information sources

General Best Practice Guidelines for Immunization

Contraindication

- A condition in a recipient that increases the risk for a serious adverse reaction
- Action: Do **NOT** give the vaccine dose

Precaution

- A condition in a recipient that might increase the risk for a serious adverse reaction, might cause diagnostic confusion, or might compromise the ability of the vaccine to produce immunity
- Action: **DEFER** the vaccine dose





- Specific questions intended to identify contraindications or precautions to vaccination
- Use of a standardized form will facilitate effective screening
- Screening must occur at every vaccination encounter (not just before the first dose)
- Following questions written from the perspective of the pediatric patient, but can be adjusted for the adult patient

- Is the child sick today?
- Does the child have an allergy to any medications, food, latex, or any vaccine?
- Has the child had a serious reaction to a vaccine in the past?

Has the child had a seizure, brain, or nerve problem?

• Has the child had a long-term problem with heart, kidney, lung (including asthma) or metabolic disease (such as diabetes), or a blood disorder?

- Does the child have cancer (e.g., leukemia), HIV/AIDS, or any other immune system problem?
- Has the child taken prednisone, other steroids, or anticancer medications, or had x-ray treatments in the past 3 months?

- Has the child received a transfusion of blood or blood products, or been given a medicine called "immune (gamma) globulin" in the past year?
- Is the child/teen pregnant or is there a chance she could become pregnant during the next month?

• Has the child received vaccinations in the past 4 weeks?

Screening Checklist

PATIENT NAME.

for Contraindications DATE OF BIRTH to Vaccines for Children and Teens

For parents/guardians: The following questions will help us determine which vaccines your child may be given today. If you answer "yes" to any question, it does not necessarily mean your child should not be vaccinated. It just means additional guestions must be asked. If a guestion is not clear, please ask your healthcare provider to explain it. don't yes no know 1. Is the child sick today? 2. Does the child have allergies to medications, food, a vaccine component, or latex? 3. Has the child had a serious reaction to a vaccine in the past? 4. Does the child have a long-term health problem with lung, heart, kidney or metabolic disease (e.g., diabetes), asthma, a blood disorder, no spleen, complement component deficiency, a cochlear implant, or a spinal fluid leak? Is he/she on long-term aspirin therapy? 5. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider told you that the child had wheezing or asthma in the past 12 months? 6. If your child is a baby, have you ever been told he or she has had intussusception? 7. Has the child, a sibling, or a parent had a seizure; has the child had brain or other nervous system problems? 8. Does the child have cancer, leukemia, HIV/AIDS, or any other immune system problem? 9. Does the child have a parent, brother, or sister with an immune system problem? 10. In the past 3 months, has the child taken medications that affect the immune system such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis. Crohn's disease, or psoriasis: or had radiation treatments? 11. In the past year, has the child received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug? 12. Is the child/teen pregnant or is there a chance she could become pregnant during the next month? 13. Has the child received vaccinations in the past 4 weeks? FORM COMPLETED BY DATE____ FORM REVIEWED BY DATE

Did you bring your immunization record card with you? yes no

It is important to have a personal record of your child's vaccinations. If you don't have one, ask the child's healthcare provider to give you one with all your child's vaccinations on it. Keep it in a safe place and bring it with you every time you seek medical care for your child. Your child will need this document to enter day care or school, for employment, or for international travel.



Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org

www.immunize.org/catg.d/p4060.pdf • Item #P4060 (10/20)

Information for Healthcare Professionals about the Screening Checklist for Contraindications to Vaccines (Children and Teens)

Are you interested in knowing why we included a certain question on the screening checklist? If so, read the information below. If you want to find out even more, consult the references in Notes below.

NOTE: For supporting documentation on the answers given below, go to the specific ACIP vaccine recommendation found at the following website: www.cdc.gov/vaccines/hcp/acip-recs/index.html

1. Is the child sick today? [all vaccines]

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (such as otitis media, upper respiratory infections, and diarrhea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics.

2. Does the child have allergies to medications, food, a vaccine component, or latex? [all vaccines]

An anaphylactic reaction to latex is a contraindication to vaccines that contain latex as a component or as part of the packaging (e.g., vial stoppers, prefilled syringe plungers, prefilled syringe caps). If a person has anaphylaxis after eating gelatin, do not administer vaccines containing gelatin. A local reaction to a prior vaccine dose or vaccine component, including latex, is not a contraindication to a subsequent dose or vaccine containing that component. For information on vaccines supplied in vials or syringes containing latex, see www.cdc.gov/vaccines-pubs/ pinkbook/downloads/appendices/B/latex-table.pdf; for an extensive list of vaccine components, see www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2. odf. People with egg allergy of any severity can receive any recommended influenza vaccine (i.e., any IIV, RIV, or LAIV) that is otherwise appropriate for the patient's age and health status. With the exception of ccIIV and RIV (which do not contain egg antigen), people with a history of severe allergic reaction to egg involving any symptom other than hives (e.g., angioedema, respiratory distress), or who required epinephrine or another emergency medical intervention, the vaccine should be administered in a medical setting, such as a clinic, health department, or physician office; vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions.

3. Has the child had a serious reaction to a vaccine in the past? [all vaccines]

History of anaphylactic reaction (see guestion 2) to a previous dose of vaccine or vaccine ent is a contraindication for subsequent doses. History of encephalopathy within 7 days following DTP/DTaP is a contraindication for further doses of pertussis-containing vaccine. There are other adverse events that might have occurred following vaccination that constitute contraindications or precautions to future doses. Under normal circumstances, vaccines are deferred when a precaution is present. However, situations may arise when the benefit outweighs the risk (e.g., during a community pertussis outbreak).

4. Does the child have a long-term health problem with lung, heart, kidney, or metabolic disease (e.g., diabetes), asthma, a blood disease (e.g., disbetes), asthma, a blood diseader, no aspiral fluid leak? Is heyche on long-term ponent deficiency, a cocheae implant, or a spiral fluid leak? Is heyche on long-term aspirin therapy? [MMR, MMRV, LAIV, VAR]

A history of thrombocytopenia or thrombocytopenic purpura is a precaution to MMR and MMRV vaccines. The safety of LAIV in children and teens with lung, heart, kidney, or metabolic disease (e.g., diabetes), or a blood disorder has not been established. These conditions, including asthma in children ages 5 years and older, should be considered precautions for the use of LAIV. Children with functional or anatomic asplenia, complement deficiency, cochlear implant, or CSF leak should not receive LAIV. Children on long-term aspirin therapy should not be given LAIV; instead, they should be given IIV. Children with CSF leak, anatomic or functional asplenia, or cochlear implant, or on long-term aspirin therapy should not be given LAIV; instead, they should be given IIV. Aspirin use is a precaution to VAR.

5. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider told you that the child had wheezing or asthma in the past 12 months? [LAIV] Children ages 2 through 4 years who have had a wheezing episode within the past 12 months should not be given LAIV. Instead, these children should be given IIV.

6. If your child is a baby, have you ever been told that he or she has had intussusception?

Infants who have a history of intussusception (i.e., the telescoping of one portion of the intestine into another) should not be given rotavirus vaccine.

7. Has the child, a sibling, or a parent had a seizure; has the child had brain or other nervous system problem? [DTaP, Td, Tdap, IIV, LAIV, MMRV]

DTaP and Tdap are contraindicated in children who have a history of encephalopathy within 7 days following DTP/DTaP. An unstable progressive neurologic problem is a precaution to the use of DTaP and Tdap. For children with stable neurologic disorders (including seizures) unrelated to vaccination, or for children with a family history of seizures, vaccinate as usual (exception: children with a personal or family [i.e., parent or sibling) history of seizures generally should not be vaccinated with MMRV; they should receive separate MMR and VAR ines). A history of Guillain-Barré syndrome (GBS) is a consideration with the following: 1) Td/Tdap: if GBS has occurred within 6 weeks of a tetanus-containing vaccine and decision is made to continue vaccination, give Tdap instead of Td if no history of prior Tdap;

www.immunize.org/catg.d/p4060.pdf + Item #P4060 - page 2 (10/20)

https://www.immunize.org/

go to the ACIP's General Best Practice Guidelines for Immunization at www.cdc.gov/ vaccines/hcp/acip-recs/general-recs/contraindications.html 2) Influenza vaccine (IIV, LAIV, or RIV): if GBS has occurred within 6 weeks of a prior influenza vaccination, vaccinate with IIV if at high risk for severe influenza complications.

8. Does the child have cancer, leukemia, HIV/AIDS, or any other immune system problem? [LAIV, MMR, MMRV, RV, VAR]

NOTE: For summary information on contraindications and precautions to vaccines.

Live virus vaccines (e.g., MMR, MMRV, VAR, RV, LAIV) are usually contraindicated in immuno compromised children. However, there are exceptions. For example, MMR is recommended for asymptomatic HIV-infected children who do not have evidence of severe immuno suppression. Likewise, VAR should be considered for HIV-infected children age 12 months through 8 years with age-specific CD4+ T-lymphocyte percentage at 15% or greater, or for children age 9 years or older with CD4+ T-lymphocyte counts of greater than or equal to 200 cell/µL. VAR should be administered (if indicated) to persons with isolated humoral munodeficiency. Immunosuppressed children should not receive LAIV. Infants who have been diagnosed with severe combined immunodeficiency (SCID) should not be given a live virus vaccine, including RV. Other forms of immunosuppression are a precaution, not a contraindication, to RV. For details, consult ACIP recommendations (see references in Notes above).

9. Does the child have a parent, brother, or sister with an immune system problem? IMMR, MMRV, VARI

MMR, VAR, and MMRV vaccines should not be given to a child or teen with a family history of congenital or hereditary immunodeficiency in first-degree relatives (i.e., parents, siblings) unless the immune competence of the potential vaccine recipient has been clinically substantiated or verified by a laboratory.

10. In the past 3 months, has the child taken medications that affect the immune system such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis; or had radiation treatments? ILAIV, MMR, MMRV, VARI

Live virus vaccines (e.g., LAIV, MMR, MMRV, VAR) should be postponed until after chemotherapy or long-term high-dose steroid therapy has ended. For details and length of time to postpone, consult the ACIP statement. Some immune mediator and immune modulator drugs (especially the antitumor-necrosis factor agents adalimumab, influimab, and etaner cept) may be immunosuppressive. A comprehensive list of immunosuppressive immune modulators is available in CDC Health Information for International Travel (the "Yellow Book") available at wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations limmunocompromised travelers. The use of live vaccines should be avoided in persons taking these drugs. To find specific vaccination schedules for stem cell transplant (bone marrow transplant) patients, see General Best Practice Guidelines for Immunization (referenced in Notes above). LAIV, when recommended, can be given only to healthy nonpregnant people ages 2 through 49 years.

11. In the past year, has the child received a transfusion of blood/blood products, or been given immune (gamma) globulin or an antiviral drug? [MMR, MMRV, LAIV, VAR] Certain live virus vaccines (e.g., MMR, MMRV, LAIV, VAR) may need to be deferred, depend-

ing on several variables. Consult the most current ACIP recommendations (referenced in Notes above) for the most current information on intervals between antiviral drugs. immune globulin or blood product administration and live virus vaccines.

Is the child/teen pregnant or is there a chance she could become pregnant during the next month? [HPV, IPV, LAIV, MenB, MMR, MMRV, VAR]

Live virus vaccines (e.g., MMR, MMRV, VAR, LAIV) are contraindicated one month before and during pregnancy because of the theoretical risk of virus transmission to the fetus. Sex ually active young women who receive a live virus vaccine should be instructed to practice careful contraception for one month following receipt of the vaccine. On theoretical grounds, IPV and MenB should not be given during pregnancy; however, it may be given if there is a risk of exposure. IIV and Tdap are both recommended during pregnancy. HPV vaccine is not recommended during pregnancy.

13. Has the child received vaccinations in the past 4 weeks? [LAIV, MMR, MMRV, VAR, yellow fever

Children who were given either LAIV or an injectable live virus vaccine (e.g., MMR, MMRV, VAR, vellow fever) should wait 28 days before receiving another vaccination of this type (30 days for yellow fever vaccine). Inactivated vaccines may be given at the same time or at any spacing interval.

VACCINE ABBREVIATIONS

LAIV = Live attenuated influenza vaccine	MMRV = MMR+VAR vaccine
HPV = Human papillomavirus vaccine	RIV = Recombinant influenza vaccine
IIV = Inactivated influenza vaccine	RV = Rotavirus vaccine
ccIIV - cell culture inactivated influenza vaccine	Td/Tdap = Tetanus, diphtheria, (acellular
IPV = Inactivated poliovirus vaccine	pertussis) vaccine
MMR = Measles, mumps, and rubella vaccine	VAR = Varicella vaccine

Invalid Contraindications and Precautions

- Disease exposure
- Mild illness or convalescence
- Preterm birth
- Breastfeeding
- Allergy to products not present in vaccine or allergy that is not severe (e.g., anaphylactic)
- Antibiotics therapy
- Pregnant person in the household
- Family history of adverse events after vaccination
- Tuberculin skin testing

Invalid Contraindications

Mild illness

Vaccinate with

- Low -grade fever
- Upper respiratory infection
- Otitis media
- Mild diarrhea

Household Contacts and Pregnancy

Susceptible household contacts of pregnant women

- Should receive MMR, varicella, zoster, and rotavirus vaccines
- *Should* receive either non-live influenza vaccine or LAIV

Invalid Contraindications

Preterm birth (less than 37 weeks)

- Generally, infants and children should be vaccinated according to chronologic age (not gestational age)
- Use full recommended dose
- Birth weight and size not factors but, as with all rules, there are exceptions (HepB)

Family History of Adverse Events

 Family history of adverse events after vaccination or medical conditions are generally NOT a contraindication

Family history of a congenital immunosuppressive condition is a temporary contraindication to MMR and varicella vaccines

 Requires screening to assure the condition is not inherited prior to receipt of MMR and varicella vaccine

Family history can be a precaution

• Example: Family history of seizures is a precaution to MMRV

Knowledge Check

- A pregnant woman living in a household is a contraindication to administering measles-mumpsrubella (MMR) or varicella (VAR) vaccines to a healthy child in the same household.
- A. True
- B. False



Answer

A pregnant woman living in the household is a contraindication to administering measles-mumpsrubella (MMR) or varicella (VAR) vaccines for a healthy child in the same household.

B. False



Screening Checklist

https://www.immunize.org/catg.d/p4060.pdf

Screening Checklist for Contraindications DATE OF BRETH to Vaccines for Children and Teens والمحداقين ليرطحه والمتبالية سنادينا For paraeta/guardianas The following questions will help us determine which vaccines your child may Be given today. If you arosen "per" to any question, it does not necessarily mean your child should not be vectivated. It just means additional questions must be saled. If a question is not clear, please advyour healthcare provider to explain it. -----**344** -1. Is the child sick today? 2. Does the child have allergies to medications, flood, a vacaine component, or later? 3. Has the child had a serious reaction to a vectine in the pest? 4. Has the child had a health problem with lung, heart, lidney or metabolic disease (e.g., diabetec), anthma, or a blood disorderif is he/she on long term aspire therapp? If the child to be vaccinated in 2 through 4 years of age, has a healthcare provider taild you that the child had wheeting or assives in the past 12 reanths? 6. If your child is a baby, have you ever been taild be or she has had intrassusception? 7. Has the child, a sibling, or a parent had a seizure; has the child had brain ar other menvous system problems? 8. Does the child or a family member have cancer, leukenia, HM(MDS, or any other Immune system problems? 9. In the past 3 months, has the child taken readications that affect the immune system such as predictions, other stanoids, or anticancer diago; drugs for the treatment of rhaumaterial articitis, Crohn's disease, or peortasis; or had radiation treatments? 10. In the past year, has the child received a transferior of blood or blood products. or been given immune (gamma) globulin or an antiviral drug? 11. Is the child/teen program or is there a chance she could become program during the next month? 122. Has the child received vaccinations in the past 4 weeks? FORM COMPLETED I HEPERENCES. PORM REVIEWED BY. DATE. Did you being your immunitation meand card with you? you 🗆 no 🗆 It is important to have a personal record of your child's vaccinations. If you don't have one, ask the child's healthcare provider to give you one with all your child's vazzinations on it. Keep it in a safe place and bring It with you every time you usek medical care for your child. Your child will even this decompart to enter day care or school, for employment, or for international taxed. ual. Minnesota - 651-647-9089 - wansimmuniza.org - m administration.org www.inemurics.org/orig/0p/000ip/11- kars-074008-05/10

Information for Healthcare Professionals about the Screening Checklist for Contraindications (Children and Teens)

Are you interested in knowing why we included a certain question on the screwing checklist? ("so, mod the information before. If you want to find out even mass, consult the references listed at the end.

and being these the state and a same or register.

time have blick as not

alls https://www.of.you.box.box.box

giller, by Nay, and Loss, Aduate

 Table of Marcine Comparently were strapped; ON consultant procise galaxies for investigation that for their features of the unter all all gladeside that we depend any the triansate light Manufacture as investigation for the second With the basis front of the formation of the formation of the second sec Lateria file the Polyging two with problem in gradients in the problem.

5 (3) Proving and match if many skilleness

and mapping the bandward from a window with Alter state from the state of the State Comparison of polycelectral (a)
 Comparison of the comparis Summittee provided high Charter Matterson France (M. Stational State

Immeniation Artice Caribics * Selet Rul, Minneseta * 607-647-9009 * www.immunize.org * www.readminifermation.org

warrin marine anglesig Algobiolipally item #74880 -- page 2 (5/12)

the sector has seen below a top. think bills it's maked a construct and

India and Republic law through

And in case of the local division of the loc

 K. Basha, early, set data markets at the bash fills of the bash fills at the bash fills at the bash fills are placed as a set of the set of the bash fills. the second second second second 2. (K. Anartine all online in constitutions) . Not a country by in the grade depheter of the state of the second s

Vaccine Safety

Comparison of 20th Century Annual Morbidity and Current Morbidity: Vaccine- Preventable Disease

Disease	20th Century Annual Morbidity [†]	2020 Reported Cases ††	Percent Decrease
Smallpox	29,005	0	100%
Diphtheria	21,053	1	> 99%
Measles	530,217	13	> 99%
Mumps	162,344	621	> 99%
Pertussis	200,752	5,398	97%
Polio (paralytic)	16,316	0	100%
Rubella	47,745	6	> 99%
Congenital Rubella Syndrome	152	0	100%
Tetanus	580	15	97%
Haemophilus influenzae	20,000	11*	> 99%

⁺ JAMA. 2007;298(18):2155-2163

⁺⁺ Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, Weekly Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance. Available at:

https://wonder.cdc.gov/nndss/nndss_weekly_tables_menu.asp?mmwr_year=2020&mmwr_week=53. Accessed on January 7, 2021.

* Haemophilus influenzae type b (Hib) < 5 years of age. An additional 7 cases of Hib are estimated to have occurred among the 136 notifications of Haemophilus influenzae (< 5 years of age) with unknown serotype.


National Center for Immunization & Respiratory Diseases



Historical Comparisons of Vaccine-Preventable Disease Morbidity in the U.S.

Importance of Vaccine Safety

- Decreases in disease risks and increased attention on vaccine risks
- Public confidence in vaccine safety is critical
 - Higher standard of safety is expected of vaccines
 - Vaccines generally healthy (vs. ill for medications)
 - Lower risk tolerance = need to search for rare reactions
 - Vaccination universally recommended and mandated



What is "Safe"?

SAFE = No harm from the vaccine

• No vaccine is 100% safe

SAFE = No harm from the disease

• No vaccine is 100% effective

Remind parents that to do nothing is to take a risk

Pre-clinical Vaccine Safety Studies


Laboratory

Animals




Prelicensure Human Studies

- Phase I, II, III trials
- Phase III trials usually include a control group that receives a placebo
- Common adverse reactions are identified
- Most Phase III trials include 2,000 to 5,000 participants
- Largest recent Phase III trial was REST (rotavirus) around 70,000 infants



Post-licensure Vaccine Safety Monitoring

- Identify rare adverse reactions
- Monitor increases in known adverse reactions—identify risk factors for reactions
- Identify vaccine lots with increased rates of reactions
- Identify "signals"—reports of adverse events more numerous than would be expected



3

Federal Vaccine Safety Monitoring

VAERS is the nation's early warning system for vaccine safety



VAERS

Vaccine Adverse Event Reporting System

Primarily a safety signal detection and hypothesis generating system

http://vaers.hhs.gov





VAERS accepts all reports from everyone regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event


key strengths

- Rapidly detects potential safety problems
- Can detect rare adverse events

key limitations

- Inconsistent quality and completeness of information
- Generally, cannot determine cause and effect

Limitations of VAERS Database



- **VAERS only contains partial data in pink cell (incomplete population data)**
 - Not able to calculate rates of occurrence of adverse events
 - Not able to determine increased risk for adverse events

Which Adverse Events Should be Reported to VAERS?

- <u>Required</u> reporting for healthcare providers¹:
 - Any adverse event listed by the vaccine manufacturer as a contraindication to further doses of the vaccine
 - Any adverse event listed in the VAERS Reportable Events Table² following vaccination that occurs within the specified time period after vaccination
- Healthcare providers are <u>encouraged</u> to report any clinically significant or unexpected adverse events (AEs) following any vaccination

Vaccine Adverse Event Reporting System (VAERS) and VAERS Reporting Form

VAERS reporting methods

- Option 1: online reporting tool (preferred)
- Option 2: writable PDF form combined with electronic document upload capability

VAERS Vaccine Adverse Event Reporting S www.vaers.hhs.gov	Adverse Event Reporting System www.vaers.hhs.gov Patient identity is kept confidential. In					r problems that occur during or after vaccination ESSENTIAL and should be completed. tructions are provided on the last two pages.				
INFORMATION ABOUT THE PATIENT WI	HO RECEIVED	THE VACO								
1. Patient name: (first) (last)				riptions, over-the					ments, or	
Street address:			herba	I remedies being t	aken at t	he time o	f vaccinati	on:		
City: County: County:										
ZIP code: Phone: () Email:			10. Aller	rgies to medicatio	ns, food,	or other p	products:			
2. Date of birth: (mm(dd(yyyy)	Female 🔲	Unknown								
 Date and time of vaccination: (mm(dd/yyyy) T 	me: hh:mm		11. Oth	er illnesses at the	time of v	accinatio	n and up to	one m	onth prior:	
5. Date and time adverse event started: (mm(dd)yyy) m T	me: hh:mm									
6. Age at vaccination: Years Months 7. Today's date: (mm/dd/yyy	r)	m	12. Chro	onic or long-stand	ing health	condition	15:			
 Is the report about vaccine(s) given to a pregnant woman?: No No (If yes, describe the event, any pregnancy complications, and estimated due date if key 	Unknown nown in item 18).	🗆 Yes								
INFORMATION ABOUT THE PERSON COMPLETING THIS FORM		INFORM	ATION A	BOUT THE FAC	LITY W	IERE VA	CCINE WA	S GIVE	EN	
13. Form completed by: (name)	15. Fa	cility/clinic	name:				of facility:			
Relation to patient: A Healthcare professional/staff Patient (yourself)						Dector	's office o	r hospit	al	
Parent/guardian/caregiver Other:	Fax: ()			0	Pharm	acy or drug	store		
Street address:	Street	address:		Check if same as its	m 13.	Workpi	lace clinic			
City: State: VIP code:	em 1.					Public	health clin	ic		
City: State: 21P code: Phone: () Email:									iving facilit	
	City:					School	(student h	ealth cli	inic	
14. Best doctor/healthcare Name: professional to contact Dhamat () Set	State:			code:		0ther:				
about the adverse event: Phone: () Ext:	Phone:	()			1	Unkno	wn			
WHICH VACCINES WERE	CONTROL MILLA	THADDER	ITD TO T	INF BATIFATS						
elect			• 1			-			select _	
elect	e cine fine es		1	50	lect lect		select select	-	select	
		urse, etc.)	-	21. Result or o Doctor or of Emergency Hospitalizat Hospital nam Gity: Prolongatio (raccine rece Ufe threate	lect utcome o ther healt room or e ion: Numl e: n of exist ived during	f adverse hcare pro mergency ber of day ing hospit existing h	select event(s): (fessional o departme is (if known Sta alization ospitalizatio	Check al ffice/cl nt visit) de:	inic visit	
	Use Continu	urse, etc.)	-	21. Result or o Doctor or of Emergency Hospitalizat Hospital nam City: Prolongation (vaccine rece	lect utcome o ther healt room or e ion: Numl e: nof exist ived during ning illnes	f adverse hcare pro mergency ber of day ing hospit existing h is immedia	select event(s): (fessional o departments (if known) Sta alization ospitalizatio ate risk of d	Check al ffice/cl nt visit) de:	inic visit	
 Describe the adverse event(s), treatment, and outcome(s), if any: symptom 	Use Continu	urse, etc.)	-	21. Result or o Doctor or of Emergency Hospitalizat Hospital nam City: Prolongatio (vaccine rece Ulfe threate	lect utcome o ther healt room or e ion: Numl e: n of exist wed during ning illnes permaner	f adverse hcare pro mergency ber of day existing h as firmedia it damage	select event(s): (fessional o departments (if known) Sta alization ospitalizatio ate risk of d	check al ffice/cl nt visit de: n) eath from	inic visit	
 Describe the adverse event(s), treatment, and outcome(s), if any: symptom 	Use Continu	urse, etc.)	if needed.	21. Result or o Octor or of Emergency Hospitalizat Hospital nam Gry: Prolongatio (raccine rece Ufe threate Disability or Patient died: Congenital a	lect utcome o ther healt room or e ion: Numl e: nof existi wed during ning illnes permanen Date of o nomely o	each damage feath	select event(s): (fessional o departme is (if known s) (if known Sta alization espitalizatio ate risk of d	check al ffice/cl nt visit de: n) eath from	inic visit	
 Describe the adverse event(s), treatment, and outcome(s), if any: symptom 	Use Continu is dates) Use Continu	urse, etc.)	if needed.	21. Result or o Octor or o' Emergency Hospitalizat Hospital nam Giy: Prolongatio fraccine rece Life threate Disability or Patient died:	lect utcome o ther healt room or e ion: Numl e: nof existi wed during ning illnes permanen Date of o nomely o	each damage feath	select event(s): (fessional o departme is (if known s) (if known Sta alization espitalizatio ate risk of d	check al ffice/cl nt visit de: n) eath from	inic visit	
 Describe the adverse event(s), treatment, and outcome(s), if any: (symptom provide the second se second second sec	Use Contins le dates) Use Contins o Unkr	urse, etc.) eation Page eation Page	if needed.	21. Result er o 0 ector or ei Emergency Hospitalizat Hospitalizat Hospitalizat Prolongatio fraccine rece Life threate Disability er Patient died: Congenital e None of the	lect utcome o ther healt room or e ion: Numl e: nof existi wed during ning illnes permanen Date of o nomely o	each damage feath	select event(s): (fessional o departme is (if known s) (if known Sta alization espitalizatio ate risk of d	check al ffice/cl nt visit de: n) eath from	inic visit	
 Describe the adverse event(s), treatment, and outcome(s), if any: (symptom Medical tests and laboratory results related to the adverse event(s); (indud Has the patient recovered from the adverse event(s)?: Yes N 	Use Contins le dates) Use Contins o Unkr MATION (Use 6	urse, etc.) eation Page eation Page	if needed.	21. Result er o 0 ector or ei Emergency Hospitalizat Hospitalizat Hospitalizat Prolongatio fraccine rece Life threate Disability er Patient died: Congenital e None of the	lect utcome o ther healt room or e ion: Numl e: nof existi wed during ning illnes permanen Date of o nomely o	each damage feath	select event(s): (fessional o departme is (if known s) (if known Sta alization espitalizatio ate risk of d	check al ffice/cl nt visit de: n) eath from	inic visit	
Describe the adverse event(s), treatment, and outcome(s), if any: Symptom Medical tests and laboratory results related to the adverse event(s); indud Medical tests and laboratory results related to the adverse event(s); indud Model tests and laboratory results related to the adverse event(s); indud Model tests adverse event(s); indud Model tests adverse event(s); indud Model tests adverse event(s); indud	Use Contins fe dates Use Contins Use Contins O Unkr MATION (Use f em 4:	urse, etc.) sation Page sation Page town	if needed. if needed.	21. Result or 0 Dector or o' Emergency Hospitalizat Hospitalizat Hospitalizat Hospitalizat Disability or Patient died: Congenital a None of the f needed).	lect utcome o ther healt room or e ion: Numl e: nof existi wed during ning illnes permanen Date of o nomely o	f adverse hcare pro mergency ber of day ing hospit existing h is fimmedia t damage feath birth def	select event(s): (fessional o departme s (if known sta alization espitalizatio te risk of d ect Body site	check al ffice/cl nt visit de: n) eath from	inic visit	
Describe the adverse event(s), treatment, and outcome(s), if any: (symptom Medical tests and laboratory results related to the adverse event(s): Medical tests and laboratory results related to the adverse event(s): Medical tests and laboratory results related to the adverse event(s): Medical tests and laboratory results related to the adverse event(s): Medical tests and laboratory results related to the adverse event(s): Medical tests and laboratory results related to the adverse event(s):	Use Contins fe dates Use Contins Use Contins O Unkr MATION (Use f em 4:	urse, etc.) sation Page sation Page town	if needed. if needed.	21. Result or 0 Dector or o' Emergency Hospitalizat Hospitalizat Hospitalizat Hospitalizat Disability or Patient died: Congenital a None of the f needed).	ect utcome o ther healt room or e ion: Numl e: mof existi wed during ning illnes permaner Date of o nomaly or above	f adverse hcare pro mergency ber of day ing hospit existing h is fimmedia t damage feath birth def	select event(s): (fessional o departme 's (if known Sta alization ospitalizatio ate risk of d ect	check al ffice/cl nt visit de: n) eath from	m the event (mm(dd)yyyy	
Describe the adverse event(s), treatment, and outcome(s), if any: fsymptom Medical tests and laboratory results related to the adverse event(s); Has the patient recovered from the adverse event(s)?: Yes N ADDITIONAL INFORM Z2. Any other vaccines received within one month prior to the date listed in its Vaccine lipsy and leand name) Manufacturer elect	Use Contins le dates) Use Contins Use Contins Use Contins Use t m 4: r	urse, etc.) eation Page nown Continuation	if needed. if needed. on Page i Lot nu	21 Result or o 0 Dector or or 0 Energency Mospitalizit Mospitalizit Prolongation Income of the function of the fun	ect utcome o ther healt room or e ion: Numl r. n of existi wed duing ning illnes permaner Date of o nomaly or above	f adverse hcare pro mergency ber of day ing hospit existing h ss (immedi t damage feath birth def	select event(s): (fessional o departme is lif known Sta alization espitalizatio espitalizatio ect Body site select select	Check al ffice/cl ffice/cl nt visit n n eath from	m the event (mmidd/yyyy Dose no. in series select	
Describe the adverse event(s), treatment, and outcome(s), if any: fsymptom Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and tests and tests adverse adverse event(s); Medical tests; Medical tests; Medical tests; Medical	Use Centias le dates) Use Centias o Unkr MATION (Use I f f 7: Øf yes, describ sian	urse, etc.) eation Page nown Continuation	if needed. if needed. on Page i Lot nu 	21 Result or o Dector or or Dector or or Hespitalext Hespitalext Hespitalext Protographic Statistic rece Ur the threate Sone of the tended. Reset tended. Reset tage at vaccination	ect utcome o coom or e ion: Numl n of existi wed during ining illness permanent Date of t noomaly or above suite suite	f adverse hcare pro- mergency ber of day ing hospit existing h is firmredia t damage feath birth def	select event(s): (fessional o departme s (if known sta alization sopitalization ate risk of d ect Body site select select select select	Check al ffice/cli nt visit te: n) eath from te:	In the event (mm)ddi/yyy Dose no. In series select select and name).	
Describe the adverse event(s), treatment, and outcome(s), if any: fsymptom Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and tests and tests adverse adverse event(s); Medical tests; Medical tests; Medical tests; Medical	Use Contins de dates Use Contins o Unkr dATION (Use t r 7: If yes, descrit sian nknown	aation Page nation Page nown Continuation e adverse en Black o Other:	if needed. if needed. Lot nu - Lot nu - ar African	21 Result or o Dector or or Dector or or Hespitalext Hespitalext Hespitalext Protographic Statistic rece Ur the threate Sone of the tended. Reset tended. Reset tage at vaccination	Lect utcome o como re como re en of existing re of existing ning illnes permanent Date of ro nomaly or onomaly or above sute lect vaccinational and a supervision of the supervision supervision of the supervision of the supervision of the supervision of the supervision of the supervision supervision of the supervision of the supervision supervision of the supervision of the supervision of the supervision supervision of the supervision of the supervis	d adverse f adverse f adverse mergency mergency margency margency	select event(s): (fessional o departme s (if known sta alization sopitalization ate risk of d ect Body site select select select select	Check al ffice/cli nt visit te: n) eath from te:	inic visit	
Describe the adverse event(s), treatment, and outcome(s), if any: fsymptom Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests and laboratory results related to the adverse event(s); Medical tests adverse recent following any previous vaccine; Mo Unknown Yes Medical adverse event following any previous vaccine; Mo Unknown Yes Medical adverse avent following any previous vaccine; Mo Unknown Yes Medical adverse event following any previous vaccine; Mo Unknown Yes Motifier Qu Qs, Patient's echnicity; Mising Qu Mot Hispanic or Latino Not Hispanic or Latino	Use Contins le dates) Use Contins o O Utekr MATION (Use M m 4: r r r ?: Øf yes, describ Sian nknown Unknown	antion Page nation Page nown Continenti e adverse en Black o Other: n 26. Im	if needed. if needed. Lot mu cuent, patient r African muniz, pro	21. Result or o 21. Result or o 21. Result or o 21. Octor or o 21. Constant or o 21. Constant of the o	ect utcome o ther health ion: Num r n of existi wed during inning illnes permanent permane	d adverse f adverse f adverse mergency mergency margency margency	select event(s): (fessional o departme s (if known sta alization sopitalization ate risk of d ect Body site select select select select	Check al ffice/cli nt visit te: n) eath from te:	m the event (mmidd/yyyy Dose no. in series select	
	Use Contins le dates) Use Contins o Unkrown AATION (Use G m4: r r ?. Of yes, describ sian nknown Unknown RY (DEPARTMI	eation Page eation Page comm Continuation Contra Continuation Continuo	if needed. if needed. on Page I - J - J - J - J - J - J - J - J - J - J	21 Result or of Chargency Hespitaleat Hespitaleat Hespitaleat Prolongation Statement Statement Chr. Prolongation Statement Statement Chargency Prolongation Statement Statem	ect utcome o tutcome o ion: Num r n of existi wed during ining illne: permaner Date of t noomaly or above suite lect vaccination for the second suite lect rescond for the second for the	deverse f adverse f adverse ber of day mg hospit sis firmeda t damage ent birth def v v v v	select event(s): (fessional o departme s (if known sta alization sopitalization ate risk of d ect Body site select select select select	Check al ffice/cl nt visit ne eath fro eath fro eath fro ther Pac	inic visit in the event in the event in the event in series select = a of name). if it is islander	

VAERS (Additional Information)

Instructions for reporting to VAERS at

<u>https://vaers.hhs.gov/reportevent.html</u>

Additional assistance

- Email at info@vaers.org
- Phone at 1-800-822-7967

Knowledge Check

- The Vaccine Adverse Event Reporting System (VAERS) can be used to establish a causal association between a vaccine and an adverse event.
- A. True
- B. False



Answer

- The Vaccine Adverse Event Reporting System (VAERS) can be used to establish a causal association between a vaccine and an adverse event.
- B. False




Post-Licensure Vaccine Safety Activities

Phase IV trials

- ~10,000 participants
- Better but still limited


Vaccine Safety Datalink (VSD)

Clinical Immunization Safety Assessment Project (CISA)



- 9 participating integrated healthcare organizations
- Data on over 12 million persons per year

VSD electronic files + chart review






42



CISA

Clinical Immunization Safety Assessment (CISA) Project

7 participating medical research centers with vaccine safety experts



clinical research

*More information about clinical consults available at <u>http://www.cdc.gov/vaccinesafety/Activities/CISA.html</u>

National Vaccine Injury Compensation Program

- Established by National Childhood Vaccine Injury Act (1986)
- "No fault" program
- Covers all routinely recommended childhood vaccines
- Vaccine Injury Table
 - <u>https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/vaccine-injury-table.pdf</u>



COVID-19 Claims

For claims associated with the COVID-19 vaccine or other COVID-19 related countermeasures, please file your Request for Benefits with the <u>Countermeasures</u> <u>Injury Compensation Program</u>.

Questions Resources

Vaccine Injury Compensation Data

Frequently Asked

Job and Advisory Committee Opportunities

Electronic filing now available for HRSA Injury Compensation Programs



Visit Injury Compensation Program's New Site! E-file with VICP or CICP at injurycompensation.hrsa.gov.

Vaccines save lives by preventing disease.

Most people who get vaccines have no serious problems. Vaccines, like any medicines, can cause side effects, but most are very rare and very mild. Some health problems that follow

The Provider's Role

Immunization providers can help ensure the safety and efficacy of vaccines through proper

- Vaccine storage and administration
- Timing and spacing of vaccine doses
- Screening of contraindications and precautions
- Management of adverse reactions
- Reporting to VAERS
- Benefit and risk communication

Benefit and Risk Communication

 Opportunities for questions should be provided before each vaccination


Vaccine information statements (VISs)


- Must be provided before each dose of vaccine
- Public and private providers
- CDC provides English versions at <u>Vaccine Information Statement | Current VISs |</u> <u>CDC</u>
- Available in multiple languages at <u>Vaccine Information Statements VISs CDC</u> <u>information sheets for patients (immunize.org)</u>



Vaccinate with Confidence


Vaccinate with Confidence: Responding to dynamics shared by recent outbreaks





Protect communities. Empower families. Stop myths.

Vaccinate with Confidence is CDC's strategic framework for strengthening vaccine confidence and preventing outbreaks of vaccine-preventable diseases in the United States



Protect communities. Empower families. Stop myths.

Protect communities

 Use every tool available to find and protect communities at risk using tailored, targeted approaches.

Empower families

 Ensure parents are confident in decision to vaccinate by strengthening provider-parent vaccine conversations.

Stop myths

 Use local partners and trusted messengers, establish new partnerships to contain the spread of misinformation, and educate critical stakeholders about vaccines.

Continuing Education Information

- CE credit, go to: <u>https://tceols.cdc.gov/</u>
- Search course number: WD4564-071922
- CE credit expires: July 1, 2024
- CE instructions are available on the Pink Book Web-on-Demand Series web page
- Questions and additional help with the online CE system, e-mail <u>CE@cdc.gov</u>



E-mail Your Immunization Questions to Us

NIPINFO@cdc.gov



Thank You From Atlanta!

